T-Cell Responses to Influenza Vaccination in Hematological Malignancy Patients

Overview

Hall et al's study reveals that influenza-specific cellular immunity is preserved in patients with hematological malignancies despite impaired humoral responses. This dissociation highlights the importance of assessing T-cell responses alongside antibody titers in this vulnerable population.

Background

Patients with hematological malignancies experience significantly higher mortality from seasonal influenza and reduced vaccine effectiveness. Most prior research has focused on humoral responses or patients with solid tumors, leaving T-cell responses in hematological malignancy patients less understood. Understanding cellular immunity is critical, as T-cell responses may better predict protection against influenza infection than antibody levels, especially in immunocompromised individuals.

Data Highlights

The study by Hall et al compared adjuvanted versus standard-dose quadrivalent inactivated influenza vaccines and single versus booster vaccination schemes, finding no significant differences in immune responses between these groups. Importantly, influenza-specific T-cell populations including IFN-γ–producing CD4⁺ and CD8⁺ T cells, mucosal-associated invariant T cells, and natural killer cells were preserved across different hematological malignancy groups, even when B-cell responses were severely blunted.

Key Findings

• Influenza-specific cellular immunity is maintained in hematological malignancy patients despite poor humoral responses.
• No significant difference in immune response between adjuvanted and standard-dose influenza vaccines or between single and booster doses.
• Dissociation between humoral and cellular immunity parallels observations in COVID-19 vaccination among patients receiving B-cell depleting therapies.
• Preserved T-cell responses suggest potential protection even when antibody responses are insufficient.
• Vaccination before or after B-cell–depleting treatments is advisable due to prolonged B-cell depletion and risk of severe influenza infection.
• Influenza vaccination uptake remains suboptimal despite good tolerability and potential for robust cellular immunity in this population.

Clinical Implications

Clinicians should consider that influenza vaccination can elicit meaningful T-cell responses in hematological malignancy patients even when antibody responses are impaired. Vaccination should not be withheld due to B-cell depletion status, and timing should prioritize early administration before or after immunosuppressive treatments. Routine assessment of cellular immunity may enhance understanding of vaccine effectiveness in this high-risk group.

Conclusion

Hall et al's findings underscore the critical role of cellular immunity in influenza vaccine responses among hematological malignancy patients and advocate for integrated evaluation of both humoral and cellular responses to optimize vaccination strategies.

References

1. Hall et al 2023 -- Immunogenicity of Influenza Vaccination in Hematologic Malignancies
2. Reference 2 -- Increased Influenza Mortality in Hematological Malignancy Patients
3. Reference 3 -- T-Cell Responses Predict Influenza Protection in Older Adults
4. References 4,5 -- Impaired Humoral Responses Post Anti-CD20 and CAR-T Therapy
5. Reference 6 -- T-Cell Immunity to COVID-19 Vaccines Despite Absent Humoral Responses
6. Reference 7 -- Waning Antibody Concentrations Post Influenza Vaccination
7. References 8,9,10 -- Vaccination Timing, Uptake, and Tolerability in Hematological Malignancies